Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Myelofibrosis, Indolent Systemic Mastocytosis

In brief

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.

Key facts

Study ID
NCT04655118
Run by
Telios Pharma, Inc.
People needed
121
Starts
2020-10-22
Expected to finish
2025-12-31
Last updated by the study team
2024-05-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.